Mach7 Technologies and 3D Medical Limited announced yesterday they have signed a definitive agreement to merge together. The merger will provide access via public capital markets for Mach7 while preserving corporate self-determination with regard to mission and product roadmap. Upon approval and completion of the agreement, the merged entity will be publicly listed on the Australian stock exchange (ASX) and will trade as "Mach7 Technologies Ltd."

Carestream Health earned the top rating in MD Buyline’s Market Intelligence Briefing (Q3 2015) for both portable and room-based digital X-ray systems for the third time this year. The company’s DRX-Revolution mobile X-ray system and its DRX-Evolution and DRX-Ascend systems scored high marks from healthcare providers for performance, reliability, installation and service quality.

Healthcare technology company MphRx will debut a new platform at the Radiological Society of North America (RSNA) 2015 annual meeting that enables transmission of detailed patient forms, images and records from any computer for review by providers and automated ingestion into an EMR, PACS or RIS.

University of Missouri, EBUS-TBFNA, lung cancer diagnosis

University of Missouri researchers have developed a new scoring system for a common lung cancer diagnostic test that may help physicians better understand the risk for malignancy when evaluating patients.

New data from clinical trials conducted at Penn Medicine’s Robert Proton Therapy Center demonstrate the technology's potential advantages over conventional radiation, including less side effects and survival in some cases, for several harder-to-treat tumors. This includes pancreatic, late-stage non-small cell lung and chordoma and chondrosarcoma, two rare cancers found in bone or soft tissue.

IBA announced that a breast cancer patient at Willis-Knighton Cancer Center has received the first U.S. Food and Drug Administration (FDA)-approved compact proton therapy treatment with cone beam computed tomography (CBCT). The treatment was completed using IBA’s Proteus One system.

Patients with intermediate meningiomas treated with radiation therapy (RT) after surgery experienced a 96 percent three-year progression-free survival rate and had minimal adverse events, according to new research. Study findings were presented at the American Society for Radiation Oncology’s (ASTRO’s) 57th annual meeting.

Candescent Health launched a software-enabled service that will allow radiologists to optimize clinical performance, increase efficiencies and deliver the most efficient and effective quality of care. Candescent was born out of 10 years of experience managing a radiology practice that achieved quality and efficiency metrics well above all industry standards. The Candescent team is now applying their expertise and technology to enable additional radiology groups to significantly optimize their care delivery models.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now